(Q37861195)

24 August 2017

1 reference

title

Management of anemia in cancer patients (English)

1 reference

24 August 2017

Aknar Calabrich

1

1 reference

24 August 2017

Artur Katz

series ordinal

2

1 reference

24 August 2017

language of work or name

English

0 references

publication date

1 April 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

7

1 reference

24 August 2017

issue

4

1 reference

24 August 2017

page(s)

507-517

1 reference

Chemotherapy-induced anemia in adults: incidence and treatment

24 August 2017

cites work

1 reference

21 January 2018

Symptomatology of anemia

1 reference

Effects of recombinant human erythropoietin (rHuEPO) on tumor control in patients with cancer-induced anemia

21 January 2018

1 reference

The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients.

21 January 2018

1 reference

Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: findings from the Anaemia Cancer Treatment (ACT) study.

21 January 2018

1 reference

The development of erythropoietic agents in oncology

21 January 2018

1 reference

Erythropoietin, uncertainty principle and cancer related anaemia

21 January 2018

1 reference

Treatment of cancer-related anemia with epoetin alfa: a review.

21 January 2018

1 reference

Risks and benefits of erythropoiesis-stimulating agents in cancer management

21 January 2018

1 reference

Erythropoietin in cancer-related anemia

21 January 2018

1 reference

Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients

21 January 2018

1 reference

Management of anemia in patients undergoing curative radiotherapy. Erythropoietin, transfusions, or better nothing?

21 January 2018

1 reference

Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis

21 January 2018

1 reference

A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue

21 January 2018

1 reference

Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy

21 January 2018

1 reference

Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies.

21 January 2018

1 reference

Epoetin alfa improves anemia and anemia-related, patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy: results of a European, multicenter, randomized, controlled trial

21 January 2018

1 reference

Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia

21 January 2018

1 reference

Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study

21 January 2018

1 reference

Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia.

21 January 2018

1 reference

Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer

21 January 2018

1 reference

EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer.

21 January 2018

1 reference

Effect of treatment with epoetin-beta on survival, tumour progression and thromboembolic events in patients with cancer: an updated meta-analysis of 12 randomised controlled studies including 2301 patients

21 January 2018

1 reference

Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis

21 January 2018

1 reference

Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials

21 January 2018

1 reference

Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia

21 January 2018

1 reference

Update on erythropoiesis-stimulating agents and clinical trials in oncology

21 January 2018

1 reference

EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update

21 January 2018

1 reference

Erythropoiesis-stimulating agents: favorable safety profile when used as indicated

21 January 2018

1 reference

American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer

21 January 2018

1 reference

Are there clinical benefits with early erythropoietic intervention for chemotherapy-induced anemia? A systematic review

21 January 2018

1 reference

Dysregulated monocyte iron homeostasis and erythropoietin formation in patients with anemia of chronic disease

21 January 2018

1 reference

Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation

21 January 2018

1 reference

Different regulatory elements are required for response of hepcidin to interleukin-6 and bone morphogenetic proteins 4 and 9.

21 January 2018

1 reference

The role of iron supplementation during epoietin treatment for cancer-related anemia

21 January 2018

1 reference

Update on adverse drug events associated with parenteral iron

21 January 2018

1 reference

Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial

21 January 2018

1 reference

Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy.

21 January 2018

1 reference

Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha.

21 January 2018

1 reference

Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia

21 January 2018

1 reference

Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy

21 January 2018

1 reference

Prognostic significance of blood transfusions in patients with esophageal cancer treated with combined chemoradiotherapy

21 January 2018

1 reference

Blood transfusion promotes cancer progression: a critical role for aged erythrocytes

21 January 2018

1 reference

Anemia, hypoxia and transfusion in patients with cervix cancer: a review.

21 January 2018

1 reference

Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer

21 January 2018

1 reference

Anemia management in oncology and hematology

21 January 2018

1 reference

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/FON.11.24

1 reference

24 August 2017

1 reference